-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21

Benzinga·08/25/2026 15:31:48
语音播报
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.